Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Non-Current Assets (2016 - 2025)

Tg Therapeutics has reported Non-Current Assets over the past 10 years, most recently at $432.5 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $432.5 million for Q4 2025, up 3716.87% from a year ago — trailing twelve months through Dec 2025 was $908.6 million (up 1789.92% YoY), and the annual figure for FY2025 was $432.5 million, up 3716.87%.
  • Non-Current Assets for Q4 2025 was $432.5 million at Tg Therapeutics, up from $425.3 million in the prior quarter.
  • Over the last five years, Non-Current Assets for TGTX hit a ceiling of $432.5 million in Q4 2025 and a floor of $11.3 million in Q4 2024.
  • Median Non-Current Assets over the past 5 years was $19.5 million (2021), compared with a mean of $65.1 million.
  • Biggest five-year swings in Non-Current Assets: tumbled 79.32% in 2023 and later skyrocketed 3716.87% in 2025.
  • Tg Therapeutics' Non-Current Assets stood at $48.7 million in 2021, then tumbled by 48.01% to $25.3 million in 2022, then plummeted by 53.97% to $11.6 million in 2023, then dropped by 2.69% to $11.3 million in 2024, then skyrocketed by 3716.87% to $432.5 million in 2025.
  • The last three reported values for Non-Current Assets were $432.5 million (Q4 2025), $425.3 million (Q3 2025), and $38.7 million (Q2 2025) per Business Quant data.